ACXP

1.0400.97%
MH

Michael H. Silverman

Medical Director

Dr. Michael H. Silverman, MD, FACP, FACR, is Medical Director of Acurx Pharmaceuticals, Inc. Dr. Silverman serves as Chief Medical Officer at Entropy Neurodynamics Limited (formerly known as Tryptamine Therapeutics Limited) since December 2022. He serves as Medical Director of OphthaliX Inc. Dr. Silverman serves as Medical Director of Can-Fite BioPharma Ltd. He founded BioStrategics Consulting Ltd. and serves as its President. He has more than twenty five years pharmaceutical industry experience in clinical development with both international pharmaceutical companies and development stage biotechnology and biopharmaceutical companies. Dr. Silverman serves as the Head of Medical Affairs of Acretia, Inc. and a Trials Consultant of Amplia Therapeutics Limited (formerly known as Innate Immunotherapeutics Limited) (formerly Innate Therapeutics Limited (formerly Virionyx Corporation Ltd)). He serves as Clinical, Regulatory and Product Development Advisor of Angstrom Pharmaceuticals, Inc. He directs Angstrom's clinical trial programs. Dr. Silverman Headed clinical research at Telor and Biopure, two biotechnology/small pharma start-up companies and was involved in management consulting in KPMG's Pharmaceutical Strategy group in 1997. Dr. Silverman is a recognized and accomplished expert in drug development and pharmaceutical clinical research. He directed clinical trials at the Sterling Winthrop Research Institute, managed therapeutics R&D at the Sandoz Research Institute. He served as a Member of Scientific Advisory Board at Taiwan Liposome Company, Ltd. He serves as a Director of Bridgewell Inc. Dr. Silverman earned his BS from the University of Illinois and his MD from the University of Chicago Pritzker School of Medicine. He completed his Internship and Medical Residency at the University of Iowa and a Fellowship in Rheumatology at the University of Colorado Medical Center.

Positions